Briacell Therapeutics Corp BCTX

$3.51 +0.01 (0.29%)

Valuation

Market cap
36,626,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
32,586
Avg volume
311,440
Day's range
$3.42 – $3.67
Shares out
8,700,000
Stochastic %K
31%
Beta
1.10
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

BHWinehouse Oct 29, 1:31 PM
$BCTX Excellence in Rare Disease Drug Development Excellence in Oncology “Biotech companies are redefining the future of cancer treatment combining cutting-edge science with an unwavering focus on patients who need new options most. This Award celebrates those leading that charge FINALISTS Arcus Biosciences with The START Center for Cancer Research BriaCell Therapeutics Candel Therapeutics Celcuity Intensity Therapeutics Kairos Pharma Legend Biotech ModeX Therapeutics
0 replies
BCTX20bMC Oct 29, 6:02 AM
$BCTX looks a lot the Apple’s stock when it went public in 1980 and almost went BK in 1997….and it literally looks like exactly every new pharma/bio company with no approved product. What’s your point? The only info you reiterate in all of your comments is that you are a cry baby.
1 replies
Rohtan Oct 29, 5:39 AM
$BCTX look at the chart. I don’t know if words can describe it.
2 replies
Biotechlineup Oct 29, 12:21 AM
$BCTX update to your “ update” Everything you just posted is misleading. Since the 10 k , there’s no difficulty in recruiting patients at all. Management said it went Hockey stick. Then recently they announced they were fully recruited. 170 each arm total 354. Just a matter of time for interim results which again management has repeatedly said year end 2026. Ample cash through 2nd qtr. no dilution. So what’s the reality. Results as expected we get a moon shot. Disappointing? Well then you risk losing. That’s biotech. Any other spin is just nonsense.
3 replies
2maligators Oct 28, 10:41 PM
$BCTX mf
1 replies
MooseG Oct 28, 10:28 PM
$BCTX they will need more cash mw thinks.
1 replies
StocktwitsEarnings Oct 28, 10:18 PM
$BCTX Q4 '26 Earnings Results & Recap Reported GAAP EPS of -$1.50 up 83.73% YoY
0 replies
d_risk Oct 28, 9:02 PM
$BCTX - BriaCell Therapeutics Corp. - 10K - Updated Risk Factors BCTX’s risk profile shifts toward execution: new emphasis on difficulty enrolling narrowly defined patient populations, vulnerability of trials to pandemics/geopolitics and site performance, plus intense competition from larger immunotherapy players and substantial doubt about going-concern funding needs, while prior Nasdaq listing-deficiency and “unproven market” risks are dropped. #Biotechnology #ClinicalTrials #PandemicRisk #ImmunotherapyCompetition #FundingUncertainty 🟢 Added 🟠 Removed https://d-risk.ai/BCTX/10-K/2026-10-28
0 replies